Skip to main content

Table 1 Comparison of tumor characteristics between TNBC and non-TNBC patients

From: The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion

 

TNBC (n = 43)

N (%)

Non-TNBC (n = 53)

N (%)

χ2

P-value

Total

Menopausal status

Pre

19 (44%)

25 (47%)

0.0851

p = 0.770

44

Post

24 (56%)

28 (53%)

52

Total

 

43

53

  

96

Tumor size

≤5 cm

23 (53%)

41(77%)

6.0869

p = 0.013

64

>5 cm

20 (47%)

12 (23%)

32

Total

 

43

53

  

96

Grade

1 + 2

33 (77%)

47 (89%)

1.8674

p = 0.171

80

3

8 (19%)

5 (9%)

13

Total

 

41

52

  

93

Stage

II

10 (23%)

29 (55%)

6.1913

p = 0.012

39

III + IV

24 (56%)

22 (42%)

46

Total

 

34

51

  

85

Lymph-node

Present

33 (77%)

30 (57%)

4.2687

p = 0.038

63

Absent

10 (23%)

23 (43%)

33

Total

 

43

53

  

96

Clinical response

CR

10 (23%)

41 (77%)

30.4317

p < 0.00001

51

SD

2 (5%)

3 (7%)

5

PD

31 (72%)

9 (17%)

40

Total

 

43

53

  

96

Relapse

Yes

27 (53%)

9 (23%)

25.8285

p < 0.000001

36

No

10 (23%)

40%77%)

50

Total

 

37

49

  

86

  1. Abbreviations: TNBC triple negative breast cancer, CR complete response, SD stable disease, PD progressive disease